Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Prog


General Information

Age Group




Protocol Number


Background Information

The purpose of this study is to test the safety of the study drug, pembrolizumab, in combination with a chemotherapy plus a steroid on participants with mCRPC with disease progression after being treated with a NHA. The study will determine the safety and efficacy of pembrolizumab compared to placebo (a look-alike with no active ingredients) in combination with a chemotherapy and a steroid. Pembrolizumab (MK-3475), also known as KEYTRUDA®.

For more information go to

Offered At

Inova Schar Cancer Institute
A department of Inova Fairfax Hospital
8081 Innovation Park Blvd.
Fairfax, VA 22031

Eligibility Information

  • Male participants with mCRPC in the pre-chemotherapy stage of treatment
  • Current evidence of metastatic disease
  • Additional eligibility in protocol

Ineligibility Information

  • Active autoimmune disease
  • Gastrointestinal disorders affecting absorption
  • Active central nervous system metastases
  • Additional ineligibility in protocol